KALY - Kali Inc Announces New Website To Host Shareholder Presentation After Acquisition of Patented Cannabis Extraction Proc...
November 20 2018 - 8:53AM
InvestorsHub NewsWire
Sarasota, FL -- November 20, 2018 --
InvestorsHub NewsWire -- Kali, Inc. (USOTC:
KALY) today announced publishing a new website and hosting an
online shareholder presentation from the new website. The
presentation details the company’s new cannabis pharmaceutical and
concentrates business plan following the acquisition of a patented
cannabis extraction process to include the acquisition of ongoing
pharmaceutical and concentrate research being conducted in
conjunction with the patented extraction process. The
presentation can be found on the company’s new website at www.kali-extracts.com. The narrative from the
presentation is included in its entirety below.
U.S. Patented Cannabis
Extraction Process Acquisition
Last week, Kali Inc announced the
acquisition of NCM Biotech which is the developer and owner of a
patented cannabis extraction process - U.S. Patent No. 9,199,960
entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT
MATERIALS INCLUDING THE CANNABIS PLANT.” NCM Biotech’s
current research and ongoing pharmaceutical developments come with
the acquisition.
NCM Biotech's medical advisory
team includes John N. Gaitanis, MD., Director of Child
Neurology at Tufts Medical Center/Floating Hospital for
Children; Lloyd R. Saberski, M.D., Associate Professor of
Anesthesiology and Chronic Pain Management, Yale University,
and John McMichael, Ph.D., President & CEO Beech Tree
Labs.
Kali Inc’s New Business
Plan
With the patented intellectual
property (IP), to include the existing and ongoing research and
development acquired from NCM Biotech, Kali will now concentrate on
the development of pharmaceuticals to treat various illnesses,
diseases and chronic pain as a symptom of various diagnoses.
Kali will also concentrate on the development of health and
wellness therapies. The cannabis pharmaceuticals market is
forecasted to reach $50 billion in sales by
2029. The cannabis concentrates for
wellness, edibles and recreational markets is forecasted to reach
$8.5 billion in annual sales by
2022.
Prior to the acquisition by Kali,
NCM Biotech was engaged with a number of different universities on
a number of separate research initiatives. As an example, and
as a preview of an upcoming announcement, NCM has been involved in
an ongoing study with a university in Kentucky on the use of a
cannabis therapy derived from Kali’s patented extraction process
for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
A paper on the results of the study using Kali’s patented
extraction process is anticipated to be published
soon.
Structure of the NCM Biotech
Acquisition and Disposition of Legacy
Assets
Kali issued a $1.5 million note in
exchange for 100% of the issued and outstanding shares of NCM
Biotech. In a related transaction, the majority shareholder
voting control affected through preferred shares, was assigned to
the NCM Biotech seller. No common shares of Kali were issued in the
acquisition of NCM Biotech and Kali has no intention of executing
either a reverse or forward split of Kali shares in conjunction
with the acquisition of NCM Biotech. Kali financial reports
are being updated as this presentation is drafted, and the filing
of the necessary financial statements required to bring the company
current are anticipated to be completed
imminently.
Further Updates To Expect
Soon
On the company website, shareholders
will note a new address and telephone number. A new email
address will be coming soon as well. The physical address and
new telephone number have been secured, but the transition process
is still underway. Shareholders can reach the company
electronically form the contact page on the new company
website. The old contact information will remain live for a
short period of time.
US Cannabis
Health
Kali recently announced is
partnership in a Joint Venture, called US Cannabis Health, to
combine its resources and expertise with those of Puration, Inc.
(PURA)
and Nouveau Life Pharmaceuticals, Inc. (NOUV)
to together attract partnerships with major pharmaceutical firms
for cannabis pharmaceutical developments. The CEO of North
American Cannabis Holdings has recently been named as the CEO of
the Joint Venture and a formal announcement is anticipated
soon. With both Puration and Nouveau operations in the North
Texas region, Kali will also relocate its primary operations to the
North Texas region.
The presentation today is a glimpse
of what the NCM Biotech acquisition brings. Stay tuned and
check back frequently for further details and future
updates.
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Kali, Inc.
941.444.6994
management@wavemarineservices.com
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024